This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies.  Read our Cookies Policy.
Close
Eye News
  • Features
    • Close
    • Features
    • Allied Professions
    • Humanitarian
    • Interviews
    • AI & Oculomics
    • Ophthalmology
    • Optometry
    • Podcast videos
    • Supplements
  • Education
    • Close
    • Education
    • Learning Curve
    • Quiz
    • Top Tips
    • Trainees
    • Medico-Legal
    • The Truth Behind The Headlines
    • Case Reports
    • Pete's Bogus Journey
  • Reviews
    • Close
    • Reviews
    • Book Reviews
    • Journal Reviews
    • What's trending?
    • Tech Reviews
    • My Top Five
    • The Culture Section
  • Events
  • News
  • Product Guide
  • Industry News
  • Contact us
    • Close
    • Contact us
    • Write for Eye News
  • Home
  • Reviews
  • Journal Reviews
  • OCT prognostic factors in AMD patients with peripapillary choroidal neovascularisation

OCT prognostic factors in AMD patients with peripapillary choroidal neovascularisation
Reviewed by Sofia Rokerya

3 August 2023 | Sofia Rokerya | EYE - Vitreo-Retinal
Share This

In this retrospective study the authors aimed to investigate the correlation between optical coherence tomography (OCT) findings and visual acuity outcomes after treatment with intravitreal bevacizumab (IVB) injections for age-related macular degeneration (AMD) patients with peripapillary choroidal neovascularisation (PPCNV). Data was identified by electronic medical records and patients with PPCNV temporal to the optic disc secondary to AMD were included in the study. Thirty eyes of 30 patients aged 84.3 ±6.9 years 63.3% of which were females were included. The CNV was located in the superior half in 73.3% of cases. The baseline BCVA was 0.46 ±0.62 logMAR (Snellen 20/57), average choroidal thickness was 193.2 ±22μm, and mean number of IVB injections was 7.2 ±1.9. After 12 months of treatment and follow-up, there was no significant change in BCVA (0.46 ±0.62 versus 0.56 ±0.78, p=0.28) (Snellen 20/57 vs. 20/72). (p=0.28). It was noted that eyes with greater central retinal thickness (r=-0.36, p=0.05), greater subretinal hyperreflective material (SHRM) area (r=-0.37, p=0.05), and greater sub-retinal fluid (SRF) area (r=-0.73, p<0.001) had a significantly smaller improvement in BCVA. Eyes with pigment epithelium detachment (PED) (0.68 ±0.90 versus 0.21 ±0.12, p=0.03) had a significantly worse BCVA. The data suggested that AMD-related PPCNV with greater foveal thickness, PED size, SHRM and SRF areas have worse final BCVA prognosis. Limitations of the study include its retrospective nature and relatively small study population. In addition, it is noteworthy that the location of SRF, IRF and PED which may also have influenced the visual acuity were not assessed in this study.

Optical coherence tomography prognostic factors in age-related macular degeneration patients with peripapillary choroidal neovascularisation.
Rabina G, Ayalon A, Mimounic M, et al.
OPHTHALMOLOGICA
2022;245(4):342-9.
Share This
Sofia Rokerya
CONTRIBUTOR
Sofia Rokerya

MBBS MRCOphth FRCSI, King's College University Hospital, UK.

View Full Profile
Specialty
  • EYE - Cataract
  • EYE - Cornea
  • EYE - General
  • EYE - Glaucoma
  • EYE - Neuro-ophthalmology
  • EYE - Oculoplastic
  • EYE - Oncology
  • EYE - Orbit
  • EYE - Paediatrics
  • EYE - Pathology
  • EYE - Refractive
  • EYE - Strabismus
  • EYE - Vitreo-Retinal
Archive
  • 2025
  • 2024
  • 2023
  • 2022
  • 2021
  • 2020
  • 2019
  • 2018
  • 2017
  • 2016
  • 2015
  • 2014
  • 2013

Top Of Page

9 Gayfield Square, 
Edinburgh EH1 3NT, UK.

Call: +44 (0)131 557 4184
www.pinpoint-scotland.com

WEBSITE DETAILS
  • Cookie Policy
  • Data Protection Notice
  • Privacy Policy
  • Terms and Conditions
ABOUT US
  • Who we are
  • Register
  • Contact us
  • Contributors
  • Company Awards
DIGITAL ISSUES/GUIDELINES
  • Digital issues - Library
  • Supplements - Library
  • Guidelines
Accreditations
IPSO_FLAG_TEAL 2025.png cpdcertified.png

Pinpoint Scotland Ltd (Registered in Scotland No. SC068684) | © 2025 - Website by Gecko Agency